Regeneron Pharmaceuticals (REGN) — Company Research
Last Updated: 6 July 2026
Regeneron Pharmaceuticals (NASDAQ: REGN) is the Tarrytown, New York biotechnology group behind Dupixent, the best-selling anti-inflammatory antibody in the world, and the EYLEA franchise for retinal disease. Built on its VelociSuite antibody-discovery and human-genetics platforms, the company reported record full-year 2025 revenue of $14.34bn and GAAP diluted EPS of $41.48 — but the market is fixated on the coming wave of EYLEA biosimilars and how fast the pipeline can refill the gap. This research reviews the numbers, the valuation and the risks. For live price action see our Live Charts, and check the Economic Calendar for events that move biotech stocks.
1. Company Snapshot
| Field | Value |
|---|---|
| Company | Regeneron Pharmaceuticals, Inc. |
| Ticker / Exchange | REGN / NASDAQ |
| Headquarters | Tarrytown, New York, USA (founded 1988) |
| Sector | Healthcare — biotechnology (antibody therapeutics) |
| CEO / Leadership | Leonard S. Schleifer, MD, PhD, Co-founder, President and Chief Executive Officer; George D. Yancopoulos, MD, PhD, Co-founder, President and Chief Scientific Officer |
| Employees | ~15,000 |
| Market cap | ~$68.6bn (5 Jul 2026, share price ~$654) |
| Revenue, FY2025 | $14.34bn (year ended 31 Dec 2025), +1% year on year |
| Net income, FY2025 | $4.51bn GAAP; $4.89bn non-GAAP |
| Dividend | $0.88 per quarter ($3.52 annualised, ~0.5% yield) — quarterly dividend initiated in 2025, first payment June 2025 |
| Fiscal year end | 31 December |
2. Bull & Bear Case
Bull Case
- Dupixent is a mega-blockbuster still growing: Global Dupixent net sales (recorded by partner Sanofi) reached $17.8bn in 2025, up 26%, with more than 1.4 million patients and fresh label expansions into COPD, chronic spontaneous urticaria and bullous pemphigoid extending the runway well past 2030.
- EYLEA HD is offsetting the legacy cliff: The higher-dose, longer-interval EYLEA HD grew US net sales 36% to $1.64bn in 2025 and hit a record $506m in Q4, deliberately converting patients off legacy 2mg EYLEA ahead of biosimilar entry.
- Fortress balance sheet: Regeneron ended 2025 with $18.9bn of cash and marketable securities against just $2.0bn of long-term debt — net cash of roughly $17bn that funds R&D, buybacks and the newly initiated dividend without strain.
- Deep, genetics-driven pipeline: Around 45 candidates are in clinical development, including the Libtayo oncology franchise (2025 global sales ~$1.45bn), factor XI antibodies, a Duchenne gene-therapy programme and multiple bispecific antibodies in blood cancers.
- Highly cash-generative: FY2025 free cash flow was $4.08bn (operating cash flow $4.98bn less $0.90bn capex), supporting continued repurchases and a fresh dividend while retaining ample firepower for business development.
Bear Case
- The EYLEA biosimilar cliff is now dated: Through 2025 and 2026 Regeneron settled patent litigation with Sandoz, Celltrion, Biocon and Alvotech, clearing multiple aflibercept biosimilars to launch around the end of 2026 — legacy EYLEA US sales already fell 42% to $2.75bn in 2025 and the erosion will accelerate.
- Revenue has effectively stalled: Group revenue rose just 1% in 2025 as EYLEA declines offset EYLEA HD and Libtayo growth; the company is racing to prove new launches can restore double-digit top-line growth.
- Concentration on two franchises: Dupixent and the EYLEA family still dominate economics, so any Dupixent competitive setback or faster-than-expected EYLEA erosion would hit the whole group.
- Sanofi dependency on the crown jewel: Dupixent is booked by Sanofi, with Regeneron taking a profit share through collaboration revenue ($7.33bn in 2025) — Regeneron does not fully control the pricing, promotion or commercial strategy of its single most important product.
- US drug-pricing and policy overhang: Medicare price negotiation, IRA dynamics and broader US pricing pressure fall directly on high-priced biologics like EYLEA and Dupixent.
3. Business Segments
Regeneron operates as a single business segment but reports revenue by type. The split below is for FY2025.
| Segment | % of revenue | What it is |
|---|---|---|
| Collaboration revenue | ~51% (FY2025: $7,331m) | Regeneron's share of profits and reimbursements from its Sanofi alliance (Dupixent, Kevzara; $5,884m) and its Bayer alliance (EYLEA outside the US; ~$1,447m) |
| Net product sales | ~44% (FY2025: ~$6,309m) | Products Regeneron books directly, mostly in the US: EYLEA HD and EYLEA ($4,385m), Libtayo US ($945m), plus Praluent, Evkeeza, Veopoz and others |
| Other revenue | ~5% (FY2025: $703m) | Reimbursements, licensing and other collaboration-related income |
4. Business Model & Moat
How it makes money. Regeneron discovers, develops and commercialises antibody and gene-based medicines. It books US product sales directly (EYLEA HD/EYLEA, Libtayo, Praluent, Evkeeza), and takes a profit share on globally partnered products — most importantly Dupixent and Kevzara with Sanofi, and EYLEA outside the US with Bayer — through collaboration revenue.
Unit economics. This is a high-margin business: FY2025 gross margin on net product sales was around 85%, GAAP operating income was $3.58bn and net income $4.51bn on $14.34bn of revenue. Research and development is the dominant cost line (roughly $5–6bn a year) because the entire strategy is to out-innovate rather than out-market rivals.
The moat. Two reinforcing platforms: VelocImmune and the broader VelociSuite for rapidly generating fully human antibodies, and one of the largest human-genetics databases in the industry (the Regeneron Genetics Center) that guides target selection. Combined with entrenched franchises — Dupixent's first-mover breadth across allergic and inflammatory diseases, and EYLEA HD's dosing advantage in retina — this produces durable, hard-to-replicate products, though the moat is weakest exactly where biosimilars now attack legacy EYLEA.
Capital allocation. Conservative and self-funded. Regeneron carries net cash of roughly $17bn, initiated its first quarterly dividend ($0.88/share) in 2025, repurchases stock opportunistically, and prioritises internal R&D plus selective bolt-on deals and collaborations over large debt-funded M&A.
5. Financial Health
All figures from Regeneron's earnings releases and SEC filings (10-K/10-Q, US GAAP; fiscal years end 31 December). Adjusted EPS is the company's non-GAAP diluted EPS.
| Fiscal Year | Revenue ($m) | YoY % | GAAP EPS | Adjusted EPS | Dividend/share | Long-term debt (YE, $m) |
|---|---|---|---|---|---|---|
| FY2021 | 16,072 | +89% | 71.97 | 74.66 | Nil | 1,980 |
| FY2022 | 12,173 | −24%¹ | 38.22 | 44.98 | Nil | 1,981 |
| FY2023 | 13,117 | +8% | 34.77 | 43.79 | Nil | 1,983 |
| FY2024 | 14,202 | +8% | 38.34 | 45.62 | Nil | 1,984 |
| FY2025 | 14,343 | +1% | 41.48 | 44.31 | $0.88² | 1,986 |
¹ The 2022 decline reflects the roll-off of COVID-19 antibody (REGEN-COV) revenue that had inflated 2021; excluding COVID products, the underlying base grew. ² Quarterly dividend of $0.88/share initiated in 2025 (first payment June 2025); no dividend was paid in prior years.
| Quarter | Revenue ($m) | Adjusted EPS | GAAP EPS |
|---|---|---|---|
| Q1 2026 (Mar 2026) | 3,605 | 9.47 | 6.75 |
| Q4 2025 (Dec 2025) | 3,884 | 11.44 | 7.86 |
| Q3 2025 (Sep 2025) | 3,754 | 11.83 | 13.62 |
| Q2 2025 (Jun 2025) | 3,676 | 12.89 | 12.81 |
| Q1 2025 (Mar 2025) | 3,029 | 8.22 | 7.27 |
| FY2025 total | 14,343 | 44.31 | 41.48 |
Balance-sheet and cash-flow picture: at 31 December 2025 Regeneron held $18.87bn of cash and marketable securities against $1.99bn of long-term debt and no meaningful short-term borrowings — net cash of roughly $17bn. Stockholders' equity was $31.26bn and total assets $40.56bn. FY2025 operating cash flow was $4.98bn (up from $4.42bn) against capex of $0.90bn, giving free cash flow of $4.08bn. 2026 guidance points to elevated capital expenditure of $1.1–1.3bn as the company expands manufacturing and R&D infrastructure.
6. Valuation
Raw metrics, July 2026. Not opinions on whether the stock is cheap or expensive.
| Metric | Value |
|---|---|
| Market cap | ~$68.6bn (~108.6m shares × ~$654, 5 Jul 2026) |
| Enterprise value | ~$51.7bn (market cap ~$68.6bn + total debt ~$2.0bn − cash & marketable securities ~$18.9bn, per 31 Dec 2025 balance sheet) |
| Trailing P/E (GAAP) | ~15.9x (~$654 / FY2025 GAAP EPS $41.48; ~16x on trailing-twelve-month GAAP EPS ~$41.0) |
| P/E (forward) | n/a — Regeneron does not provide EPS guidance, and ChartsView does not use analyst estimates |
| P/S (TTM) | ~4.6x (market cap ~$68.6bn / TTM revenue ~$14.9bn) |
| EV/EBITDA (TTM) | ~12.5x (EV ~$51.7bn / FY2025 EBITDA ~$4.12bn; EBITDA = GAAP operating income $3,578m + D&A $544m per FY2025 cash flow statement) |
| P/FCF | ~16.8x (market cap ~$68.6bn / FCF ~$4.08bn; FCF = FY2025 operating cash flow $4,979m − capex $898m) |
| 52-week high | $821.11 |
| 52-week low | $532.74 |
| Short interest (% of float) | ~2.8% (~2.8m shares short, late Jun 2026) |
| Days to cover | ~3.6 |
7. Growth Drivers
Four engines matter from here. First, Dupixent label expansion: on top of atopic dermatitis, asthma and eosinophilic diseases, newer indications — COPD, chronic spontaneous urticaria and bullous pemphigoid — keep widening the addressable population of a product already at a $17.8bn run-rate, and management continues to file additional indications. Second, EYLEA HD conversion: by moving retina patients onto the higher-dose, longer-interval formulation (extended dosing intervals now approved), Regeneron aims to retain franchise value even as legacy 2mg EYLEA faces biosimilars. Third, oncology: Libtayo (PD-1) is now a ~$1.45bn franchise growing double digits, complemented by a pipeline of bispecific antibodies (odronextamab and others) in blood cancers. Fourth, the deeper pipeline: roughly 45 clinical programmes spanning factor XI anticoagulation, genetic-medicine and gene-therapy plays (including a Duchenne muscular dystrophy programme), and antibody combinations — the intended long-term replacement for EYLEA economics. Elevated 2026 capital expenditure guidance of $1.1–1.3bn signals continued investment behind these engines.
8. Peer Comparison
| Peer | Market cap (Jul 2026) | Key 2025 metric |
|---|---|---|
| Sanofi (NASDAQ: SNY) | ~$135bn | Dupixent partner; 2025 group sales ~€41bn — controls Dupixent commercialisation |
| Amgen (NASDAQ: AMGN) | ~$165bn | 2025 revenue ~$34bn — launched Pavblu, the first EYLEA 2mg biosimilar |
| Vertex Pharmaceuticals (NASDAQ: VRTX) | ~$115bn | 2025 revenue ~$11.9bn — comparable large-cap biotech on scale and margins |
| AbbVie (NYSE: ABBV) | ~$390bn | 2025 revenue ~$60bn — Rinvoq/Skyrizi compete in immunology against Dupixent |
| Roche (OTC: RHHBY) | ~$280bn | Vabysmo is the principal branded rival to EYLEA HD in retinal disease |
9. Insider Activity
Recent insider activity has consisted of routine, pre-planned equity-award vesting and Rule 10b5-1 option exercises and sales by the co-founders — including CEO Leonard Schleifer and President and CSO George Yancopoulos — rather than discretionary open-market trading. No material insider open-market buying or unscheduled selling has been disclosed in recent months; SEC Form 4 filings show the pattern of scheduled option exercise-and-sell transactions typical of long-tenured founder-executives. Investors can verify the latest filings on the SEC EDGAR system.
10. Key Risks
- EYLEA biosimilar erosion (Competitive): Multiple aflibercept biosimilars (Amgen's Pavblu already launched; Sandoz, Celltrion, Biocon and Alvotech cleared to launch around end-2026) will accelerate the decline of legacy EYLEA, which still fell 42% in 2025; the pace of erosion is the single biggest swing factor for the stock.
- Franchise concentration (Financial): Dupixent and the EYLEA family generate the bulk of economics; a setback to either — competitive, clinical or commercial — would disproportionately hit group results.
- Sanofi collaboration dependency (Strategic): Dupixent is booked and commercialised by Sanofi, so Regeneron's largest profit stream depends on a partner's execution and on the durability of the collaboration terms.
- US drug-pricing policy (Regulatory): Medicare price negotiation, IRA provisions and broader pricing scrutiny bear directly on high-priced biologics such as EYLEA and Dupixent.
- Pipeline and clinical risk (Operational): The thesis relies on new launches (oncology bispecifics, factor XI, genetic medicines) replacing EYLEA economics; trial failures or slow uptake would leave a growth gap.
- Litigation and IP exposure (Regulatory): Regeneron is engaged in extensive patent litigation defending EYLEA and other assets; adverse rulings could bring biosimilar competition forward.
11. Recent Developments
- 30 Jan 2026 — Record full-year 2025 results. Revenue of $14.34bn (+1%) and GAAP EPS of $41.48 (+8%); Q4 revenue of $3.88bn led by EYLEA HD (+66%) and Sanofi collaboration profit (+42%), with Dupixent global sales reaching $17.8bn for the year.
- April 2026 — Biocon EYLEA biosimilar settlement. Regeneron settled litigation with Biocon Biologics, allowing interchangeable biosimilar Yesafili to be commercialised in the US in the second half of 2026.
- 29 Apr 2026 — Strong Q1 2026. Revenue rose 19% to $3.61bn with non-GAAP EPS up 15% to $9.47; EYLEA HD US sales jumped 52% to $468m and Dupixent grew 33% to $4.9bn in the quarter, though GAAP net income fell 10% to $727m on higher operating spend.
- Q2 2026 — Sandoz, Celltrion and Alvotech settlements. Regeneron reached patent settlements clearing additional aflibercept biosimilars (Sandoz's Enzeevu, Celltrion's and Alvotech's programmes) to launch around the end of 2026, crystallising the timeline for legacy EYLEA competition.
- 17 Jun 2026 — Corporate/pipeline update. Regeneron continued to advance its ~45-programme clinical pipeline and disclosed further regulatory and business developments ahead of its Q2 2026 report.
12. Key Dates
- 30 Jul 2026 — Q2 2026 results (scheduled, before US market open; earnings call 8:30am ET)
- 31 Dec 2026 — Fiscal year 2026 ends; approximate window for multiple EYLEA biosimilar launches
- 29 Oct 2026 — Q3 2026 results expected (estimated; prior-year cadence: reported 28 Oct 2025)
Quarterly dividends are typically declared alongside results with payment the following quarter. Discuss REGN with other members on the ChartsView Forum, and track healthcare-sector catalysts on our Economic Calendar.
Disclaimer: This research is produced by ChartsView for educational and informational purposes only. It does not constitute financial advice or a recommendation to buy or sell any security. All information is sourced from publicly available company filings, press releases, and official data. ChartsView does not use analyst opinions or third-party ratings. Always conduct your own due diligence and consider your personal financial situation before making investment decisions. Past performance is not indicative of future results.<
Loading research report…
13. Thesis Verdict
The central thesis. Regeneron discovers and commercialises antibody medicines, booking US product sales directly and taking profit shares on globally partnered drugs — above all Dupixent with Sanofi. FY2025 delivered record revenue of $14.34bn (+1%) and GAAP EPS of $41.48, with free cash flow of $4.08bn and net cash of roughly $17bn. The near-term driver is EYLEA HD conversion and continued Dupixent label expansion ahead of the EYLEA biosimilar wave.
What would confirm or break it. Confirmation would come from Q2 2026 results (30 July) landing in line with guidance and from EYLEA HD plus new launches offsetting legacy EYLEA erosion. The thesis breaks if aflibercept biosimilars — now cleared to launch around end-2026 — erode the EYLEA franchise faster than the pipeline can refill it, or if Dupixent faces a competitive or commercial setback.
Watchpoints
- ConfirmsQ2 2026 earnings (24 days) landing in line with or above management guidance.
- ConfirmsEvidence supporting the "Dupixent is a mega-blockbuster still growing:" thesis continuing to build across subsequent filings.
- InvalidatesMaterialisation of the "EYLEA biosimilar erosion (Competitive):" risk, or any disclosure that fundamentally alters the capital-return or growth profile stated by management.
Diagnostic grid
Generated by ChartsView research tooling. Thesis strength measures how well the evidence in this report supports the company's stated thesis — it is NOT a buy/sell rating or price target. ChartsView is not authorised by the FCA to provide regulated investment advice. Generated 6 Jul 2026.